Efficacy and safety results from IMblaze370, a randomised phase III study comparing atezolizumab + cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer Meeting Abstract
| Authors: | Bendell, J.; Ciardiello, F.; Tabernero, J.; Tebbutt, N.; Eng, C.; Di Bartolomeo, M.; Falcone, A.; Fakih, M.; Kozloff, M.; Segal, N.; Sobrero, A.; Shi, Y.; Roberts, L.; Yan, Y.; Chang, I.; Uyei, A.; Kim, T. |
| Abstract Title: | Efficacy and safety results from IMblaze370, a randomised phase III study comparing atezolizumab + cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer |
| Meeting Title: | ESMO 20th World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2018 Jun 20-23 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-06-01 |
| Start Page: | mdy208.003 |
| Language: | English |
| ACCESSION: | WOS:000439970900360 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy208.003 |
| Notes: | Meeting Abstract: LBA-004 -- Appears on page 123 of the abstract book -- Source: Wos |
